Preclinical study of new TB drugs and drug combinations in mouse models.
Tuberculosis (TB) remains one of the leading infectious killers in the world. New anti-TB drugs and more effective drug combinations are urgently needed, particularly given the increasing incidence of drug-resistant TB and HIV-TB co-infection. This review describes the available mouse models of TB and describes their utility in the evaluation of new TB drug candidates and in the evaluation of the efficacy of new TB drug combinations. Some of the most recent patents on promising TB drug-candidates are also mentioned here.
Nikonenko
Boris V
BV
Sequella, Inc., 9610 Medical Center Drive, Suite 200, Rockville, MD 20850, USA. borisnikonenko@sequella.com
Sacksteder
Katherine A
KA
Hundert
Sam
S
Einck
Leo
L
Nacy
Carol A
CA
D000818:Animals; D000995:Antitubercular Agents / Q000737:chemistry / Q000494:pharmacology*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D051379:Mice; D015394:Molecular Structure; D010330:Patents as Topic; D013329:Structure-Activity Relationship; D013997:Time Factors; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents